Background
Methods
Patients and surgical procedures
Follow-up after curative gastrectomy followed by adjuvant chemotherapy
Statistical analysis
Results
Clinicopathological characteristics of stage III GC patients after curative gastrectomy followed by adjuvant chemotherapy
Variables | Number | Percent |
---|---|---|
Total | 97 | |
Gender | ||
Male | 61 | 63% |
Female | 36 | 37% |
Age | ||
≥65 | 51 | 53% |
<65 | 46 | 47% |
Tumor location | ||
U | 19 | 20% |
M | 28 | 29% |
L | 32 | 33% |
Whole | 18 | 19% |
Tumor major axis(mm) | ||
≥90 | 33 | 34% |
<90 | 64 | 66% |
T-stage | ||
T2 / T3 | 27 | 28% |
T4 | 70 | 72% |
N-stage | ||
N1/ N2 | 47 | 48% |
N3 | 50 | 52% |
Histopathological type | ||
Differentiated | 31 | 32% |
Undifferentiated | 66 | 68% |
Venous invasion | ||
Present | 49 | 51% |
Absent | 48 | 49% |
Lymphatic invasion | ||
Present | 87 | 90% |
Absent | 10 | 10% |
Surgical procedure | ||
Total gastrectomy | 53 | 55% |
Distal gastrectomy | 44 | 45% |
Clinical outcomes and prognostic factors for relapse-free survival of stage III GC patients after curative gastrectomy followed by adjuvant chemotherapy
Univariatea | Multivariateb | ||||||
---|---|---|---|---|---|---|---|
N | 5-year RFSc | P-value | HRd | 95% CIe | P-value | ||
Sex | Male | 61 | 46.1% | 0.577 | 1.20 | 0.63–2.31 | 0.581 |
Female | 36 | 36.0% | |||||
Age | <65 | 46 | 42.2% | 0.824 | 1.39 | 0.76–2.53 | 0.285 |
≥65 | 51 | 41.9% | |||||
Tumor major axis(mm) | ≥90 | 33 | 30.8% | 0.092 | 1.46 | 0.71–3.21 | 0.109 |
<90 | 64 | 48.8% | |||||
T-stage | T4 | 70 | 38.9% | 0.326 | 1.46 | 0.79–3.63 | 0.311 |
T2/ T3 | 27 | 50.1% | |||||
N-stage | N3 | 50 | 33.4% | 0.339 | 1.51 | 0.82–2.84 | 0.187 |
N1/ N2 | 47 | 50.9% | |||||
Venous invasion | Present | 48 | 36.5% |
0.034
| 1.82 | 1.01–3.37 |
0.048
|
Absent | 49 | 47.4% | |||||
Lymphatic invasion | Present | 87 | 39.8% | 0.168 | 1.51 | 0.56–5.28 | 0.445 |
Absent | 10 | 40.0% |
Comparison of recurrence patterns according to stage III GC patients with or without venous invasion
Venous invasion | |||||
---|---|---|---|---|---|
N | Present | Absent | P-value | ||
Regimen | |||||
S-1 | 41 | 23(24%) | 18(19%) | 0.346 | |
S-1 plus cisplatin | 14 | 10(10%) | 4(4%) | 0.086 | |
5-FU plus methotrexate | 12 | 4(4%) | 8(8%) | 0.200 | |
UFT | 12 | 5(5%) | 7(7%) | 0.511 | |
S-1 plus paclitaxel | 7 | 2(2%) | 5(5%) | 0.221 | |
5-FU plus cisplatin | 5 | 3(3%) | 2(2%) | 0.662 | |
5-FU | 5 | 1(1%) | 4(4%) | 0.148 | |
Paclitaxel | 1 | 1(1%) | 0(0%) | 0.241 |
Venous invasion | Univariatea | ||||
---|---|---|---|---|---|
N | Present | Absent | P-value | ||
Total | 97 | 49 (51%) | 48 (49%) | 0.615 | |
Hematogenous recurrence | 12 | 10 (10%) | 2 (2%) |
0.022
| |
Liver | 8 | 7 (7%) | 1 (1%) |
0.021
| |
Lung | 2 | 2 (2%) | 0 (0%) | 0.096 | |
Bone | 2 | 1 (1%) | 1 (1%) | 0.988 | |
Lymphatic recurrence | 12 | 7 (7%) | 5 (5%) | 0.562 | |
Peritoneal recurrence | 34 | 18 (19%) | 16 (16%) | 0.726 | |
Local recurrence | 4 | 1 (1%) | 3 (3%) | 0.287 |